Drug Sponsors

AstraZeneca, Ironwood announce linaclotide collaboration for China

Friday, October 26, 2012 02:20 PM

AstraZeneca, a global biopharmaceutical company, and Ironwood Pharmaceuticals, a Cambridge, Mass.-based entrepreneurial pharmaceutical company, have signed an agreement to co-develop and co-commercialize Ironwood’s linaclotide in China.

More... »

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »

Thrasos secures $35M for THR-184 phase II program for acute kidney injury

Friday, October 26, 2012 11:39 AM

Thrasos Therapeutics, a Canadian clinical stage biotherapeutics company, has completed a $35 million financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

More... »

Aclaris raises $21M in Series A Financing

Thursday, October 25, 2012 07:30 AM

Aclaris Therapeutics, a privately held specialty pharmaceutical company focused on dermatological therapeutics, has secured $21 million in Series A financing.

More... »

Forest Laboratories, moksha8 form strategic alliance for Latin America

Wednesday, October 24, 2012 10:33 AM

Forest Laboratories, an international pharmaceutical company, and moksha8, a pharmaceutical company that commercializes CNS medicines in Latin America, have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market.

More... »

Pfizer to acquire NextWave Pharmaceuticals

Monday, October 22, 2012 12:56 PM

Pfizer, a global research-based pharmaceutical company, has agreed to acquire NextWave Pharmaceuticals, a privately-held, specialty pharmaceutical company focused on attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

More... »

AMRI, Shire ink 5-year extension of API supply agreement

Monday, October 22, 2012 12:22 PM

AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.

More... »

Alnylam, Genzyme to develop and commercialize RNAi therapeutics in Asia

Monday, October 22, 2012 12:01 PM

Alnylam Pharmaceuticals, a biopharmaceutical company based in Cambridge, Mass., and Genzyme, a Sanofi company, have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

More... »

Charles River Labs, AZ enter strategic partnership

Monday, October 22, 2012 10:43 AM

AstraZeneca, a global biopharmaceutical company, has selected Charles River Laboratories International, a global provider of research products and services, as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

More... »

Neurovance closes $7M series A1 round for ADHD drug

Friday, October 19, 2012 12:09 PM

Neurovance, has closed a $7 million series A1 round led by existing investor Novartis Venture Fund to further advance development of EB-1020 for adult attention deficit hyperactivity disorder (ADHD).

More... »